NCT02353780View on ClinicalTrials.gov

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

PHASE4TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 30, 2017

Study Completion Date

November 30, 2018

Conditions
Rheumatoid Arthritis (RA)
Interventions
DRUG

TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)

TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.

DRUG

Abatacept

Abatacept; SQ; specifics to be determined by the treating rheumatologist.

DRUG

Tocilizumab

Tocilizumab; SQ; specifics determined by the treating rheumatologist.

Trial Locations (1)

15261

University of Pittsburgh, Pittsburgh

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dr. Larry W. Moreland

OTHER

NCT02353780 - Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept | Biotech Hunter | Biotech Hunter